Thomas Lingelbach, Valneva CEO
Covid-19 roundup: Valneva runs into EMA questions, still expects March authorization; Canada approves first plant-based vaccine
In February 2021, the European Medicines Agency began a rolling review of French biotech Valneva’s Covid-19 vaccine, which is a whole virus, inactivated, adjuvanted vaccine.
About a year later, Valneva says the EMA still has questions, although the company said Friday that it’s “confident that it will be able to respond to these in the coming days. Following the Company’s response, the EMA will provide a timetable towards anticipated conditional approval.”
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
